HPS2-THRIVE: Game (Mostly) Over for Niacin (CME/CE)
(MedPage Today) -- Publication of landmark trial results affirmed no benefit and worrisome adverse events from adding extended-release niacin to statin therapy, but many physicians weren't ready to concede failure of the purported HDL mechanism.
When Tom Shicowich’s toe started feeling numb in 2010, he brushed it off as a temporary ache. At the time, he didn’t have health insurance, so he put off going to the doctor. The toe became infected, and he got so sick that he stayed in bed for two days with what he assumed was the flu. When he finally saw a doctor, the physician immediately sent Shicowich to the emergency room. Several days later, surgeons amputated his toe, and he ended up spending a month in the hospital to recover. Shicowich lost his toe because of complications of Type 2 diabetes as he struggled to keep his blood sugar under control. He wa...
ConclusionThe risk score accurately categorizes the one ‐year risk of major toxicity among NSAID users and may be useful in identifying patients who can safely use these agents.This article is protected by copyright. All rights reserved.
Diabetes mellitus (DM) increases cardiovascular morbidity and mortality. A statin is routinely prescribed to patients with DM. However, whether a statin therapy is equally effective in plaque stabilization in DM patients compared to non-DM patients is unknown. A total of 117 lipid rich plaques were imaged in 90 patients (54 plaques in 41 DM patients and 63 plaques in 49 non-DM patients) with coronary artery disease who were treated with a statin and underwent serial optical coherence tomography imaging were included in this study (mean follow up period, 362 ± 38 days).
Statins are widely used to lower cholesterol and to reduce cardiovascular events. Whether all statins have similar effects on plaque stabilization is unknown. We aimed to investigate coronary plaque response to treatment with different statins that result in similar lipid reduction using serial multimodality intracoronary imaging. Patients with de novo coronary artery disease requiring intervention were randomized to rosuvastatin 10mg (R10) or atorvastatin 20mg (A20) daily. Optical coherence tomography (OCT) and intravascular ultrasound (IVUS) were performed at baseline, 6 months, and 12 months.
The objective of this study was to investigate the effects of statin use before cardiac arrest on outcomes in cardiac arrest patients. Medical records of 142,131 adult patients who experienced non-traumatic cardiac arrest and were resuscitated between 2004 and 2011 were analyzed.
Journal of Palliative Medicine,Volume 22, Issue 3, Page 351-351, March 2019.
DiscussionFor patients with a low-to-moderate risk of CAD, we found a significant effect of rosuvastatin on retinal microvasculature, including AVR increase, venular constriction, and arteriolar dilation after 6 –12 months of treatment.Clinical Trial registrationChinese Clinical Trial Registry identifier number ChiCTR-IOR-15006664.
AbstractMultipronged risk management in diabetes has contributed to the recent decline in cardiovascular mortality. Few antihyperglycemic drugs have been conclusively shown to have cardioprotective effects. These include metformin, liraglutide, semaglutide, dulaglutide, and sodium-glucose cotransporter-2 inhibitors. Statins are the cornerstone of treatment for people with established coronary artery disease (CAD) or at risk of CAD. In patients with persistent low-density lipoprotein cholesterol (LDL-C) levels> 70 mg/dL, the addition of ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibit...
This study is a retrospective review of Cochrane CENTRAL database, MEDLINE, and Embase through June 15, 2018.